Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway

• DOI: 10.1016/j.redox.2023.102963
• Publication Date: 2023-11-16T17:49:53Z
• Authors: Tianyu Jiang; Yao Xiao; Jinfeng Zhou; Zupeng Luo; Lin Yu; Qichao Liao; Siqi Liu; Xinyi Qi; Hao Zhang; Menglong Hou; WeiWei Miao; Batbold Batsaikhan; Turtushikh Damba; Yunxiao Liang; Yixing Li; Lei Zhou
• Keywords: Arbutin

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious that affects 30 % of the global population and poses significant risk to human health. However, date, no safe, effective appropriate treatment modalities are available. In recent years, ferroptosis has emerged as mode cell death been found play key regulatory role in development NAFLD. this study, we arbutin (ARB), natural antioxidant derived from Arctostaphylos uva-ursi (L.), inhibits onset ameliorates high-fat diet-induced NAFLD vivo vitro. Using reverse docking, identified demethylase fat mass obesity-related protein (FTO) potential target ARB. Subsequent mechanistic studies revealed ARB plays controlling methylation SLC7A11 gene through inhibition FTO. addition, demonstrated could alleviate Our findings identify FTO/SLC7A11 axis therapeutic for Specifically, show alleviates by acting on pathway inhibit ferroptosis.